12:32 PM EST, 01/22/2025 (MT Newswires) -- BioAffinity Technologies ( BIAF ) said the Australian patent office accepted its patent application for the method used in the CyPath Lung diagnostic test for predicting lung cancer.

The Australian patent, expected to be issued in three months, will expire in 2042 and will be the second patent for the CyPath Lung test, the company said Wednesday in a statement.

Price: 0.68, Change: +0.01, Percent Change: +2.09